Novo Nordisk A/S (NYSE:NVO) Now Covered by Analysts at Wolfe Research

Wolfe Research started coverage on shares of Novo Nordisk A/S (NYSE:NVO) in a report released on Thursday, Marketbeat.com reports. The brokerage issued a peer perform rating on the stock.

NVO has been the topic of several other research reports. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Citigroup initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 27th. They set a “neutral” rating on the stock. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Up 0.2%

Shares of NYSE NVO opened at $36.42 on Thursday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The business’s 50 day moving average is $46.44 and its two-hundred day moving average is $50.61. Novo Nordisk A/S has a 52-week low of $35.85 and a 52-week high of $81.44. The firm has a market cap of $162.60 billion, a price-to-earnings ratio of 10.49 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 23.63%.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of hedge funds have recently bought and sold shares of NVO. Martin Capital Partners LLC increased its holdings in shares of Novo Nordisk A/S by 53.8% in the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after acquiring an additional 41,129 shares during the period. Smith Chas P & Associates PA Cpas boosted its stake in Novo Nordisk A/S by 105.3% during the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock worth $22,497,000 after purchasing an additional 207,959 shares during the period. Clifford Swan Investment Counsel LLC boosted its stake in Novo Nordisk A/S by 13.7% during the 3rd quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock worth $17,267,000 after purchasing an additional 37,453 shares during the period. Markel Group Inc. grew its position in Novo Nordisk A/S by 4.9% during the 3rd quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock worth $131,436,000 after purchasing an additional 110,061 shares during the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. purchased a new position in Novo Nordisk A/S during the 3rd quarter worth $1,294,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Hims & Hers will begin offering several of Novo Nordisk’s FDA‑approved GLP‑1 medicines, including the newly launched Wegovy pill, expanding retail distribution and patient access in the U.S., which could support sales momentum. What’s Happening With Novo Nordisk Stock Today?
• Positive Sentiment: Phase‑2 results for UBT251 (a triple GLP‑1/GIP/glucagon agonist) showed meaningful HbA1c and weight reductions versus semaglutide/placebo in Chinese patients, supporting plans for global follow‑on trials and potential long‑term growth beyond current products. Novo Nordisk Says Experimental Diabetes and Obesity Drug Shows Positive Results
• Neutral Sentiment: Novo Nordisk appointed Poul Weihrauch (Mars CEO) as a board observer to bolster U.S. commercial insight into the obesity market — a governance/strategy move that signals focus on U.S. competition but is not an immediate earnings driver. Novo Nordisk appoints Mars CEO as board observer
• Neutral Sentiment: Broker notes were mixed-to-neutral: Deutsche Bank and Citi gave broadly neutral takes on the GLP‑1 pipeline (encouraging but not transformative), and Wolfe Research initiated coverage at “peer perform” — these updates temper enthusiasm without changing fundamentals immediately. Novo Nordisk GLP-1 pipeline shows promise but oral drug trends give analysts pause
• Neutral Sentiment: The company held its Annual General Meeting; management framed 2025 as a transformational year and reiterated strategic priorities — useful for long‑term context but not an immediate stock catalyst. Resolutions from the Annual General Meeting of Novo Nordisk A/S
• Negative Sentiment: Novo Nordisk cut the U.S. market‑adjacent Wegovy price in South Africa for the second time amid fierce competition (notably from Eli Lilly), highlighting pricing pressure that could weigh on margins and revenue growth in competitive markets. Novo Nordisk cuts Wegovy price in South Africa for a second time
• Negative Sentiment: Bernstein initiated coverage with an Underperform rating and a cautious outlook, warning that the company’s earnings downgrade cycle may not be over — a note that can pressure sentiment and invites closer scrutiny from other investors. Bernstein Initiates Coverage of Novo Nordisk (NVO) With an Underperform Rating

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.